Loading...
•
Dec 31, 2021
Generation Bio Q4 2021 Earnings Report
Generation Bio's strategic priorities for 2022 were outlined and the financial results for the fourth quarter and full year 2021 were reported.
Key Takeaways
Generation Bio reported its Q4 and full-year 2021 financial results, highlighting a cash position of $375.1 million, which is expected to fund operations into 2024. The company is focused on advancing its genetic medicine platform across liver, retina, and vaccine applications.
Cash and cash equivalents totaled $375.1 million as of December 31, 2021.
R&D expenses for Q4 2021 were $21.8 million.
G&A expenses for Q4 2021 were $9.1 million.
Net loss for Q4 2021 was $30.9 million, or $0.54 basic and diluted net loss per share.
Generation Bio
Generation Bio
Forward Guidance
Generation Bio is focused on advancing its genetic medicine platform across liver, retina, and vaccine applications.
Positive Outlook
- Completing optimization of cell-targeted lipid nanoparticle (ctLNP) for the liver to advance the hemophilia A program.
- Advancing the retina ctLNP to support the Stargardt program.
- Advancing the vaccine ctLNP to enable work in vaccines.
- Evaluating more advanced generations of retina ctLNP in NHPs to enable potential selection of a development candidate for Stargardt disease.
- Evaluating a next-generation vaccine ctLNP in NHPs that has demonstrated enhanced potency in preclinical murine studies for both mRNA and ceDNA.
Challenges Ahead
- Uncertainties inherent in the identification and development of product candidates.
- Uncertainties as to the availability and timing of results from preclinical studies and clinical trials.
- Whether results from earlier preclinical studies will be predictive of the results of later preclinical studies and clinical trials.
- Uncertainties regarding the timing and ability to complete the build-out of the company’s manufacturing facility and regarding the new manufacturing process.
- Challenges in the manufacture of genetic medicine products.